Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,800
Closed -$448K 43
2021
Q1
$448K Sell
1,800
-800
-31% -$191K 0.77% 42
2020
Q4
$597K Hold
2,600
1.04% 39
2020
Q3
$660K Hold
2,600
1.22% 30
2020
Q2
$613K Hold
2,600
1.2% 32
2020
Q1
$527K Sell
2,600
-4,496
-63% -$982K 1.22% 34
2019
Q4
$1.71M Buy
7,096
+1,450
+26% +$320K 3.03% 9
2019
Q3
$1.09M Sell
5,646
-3,770
-40% -$724K 2.08% 19
2019
Q2
$1.74M Sell
9,416
-210
-2% -$37.6K 3.29% 6
2019
Q1
$1.83M Hold
9,626
3.46% 6
2018
Q4
$1.87M Hold
9,626
3.97% 3
2018
Q3
$2M Hold
9,626
3.62% 6
2018
Q2
$1.78M Sell
9,626
-20
-0.2% -$3.54K 3.51% 5
2018
Q1
$1.65M Hold
9,646
3.32% 5
2017
Q4
$1.68M Buy
9,646
+20
+0.2% +$3.54K 3.09% 7
2017
Q3
$1.79M Sell
9,626
-2,000
-17% -$354K 3.44% 7
2017
Q2
$2M Hold
11,626
3.96% 4
2017
Q1
$1.91M Hold
11,626
4.04% 4
2016
Q4
$1.7M Hold
11,626
3.94% 3
2016
Q3
$1.94M Hold
11,626
0.24% 4
2016
Q2
$1.77M Sell
11,626
-140
-1% -$21.8K 0.25% 3
2016
Q1
$1.76M Hold
11,766
0.39% 3
2015
Q4
$1.91M Hold
11,766
0.53% 3
2015
Q3
$1.63M Sell
11,766
-320
-3% -$50.4K 0.46% 3
2015
Q2
$1.86M Sell
12,086
-354
-3% -$56.7K 0.42% 2
2015
Q1
$1.99M Sell
12,440
-100
-0.8% -$15.7K 0.43% 2
2014
Q4
$2M Buy
+12,540
New +$1.95M 0.44% 3

Other funds holding AMGN

Jay D. Rosenbaum's AMGN Position: Q2 2021 in Review

Jay D. Rosenbaum sold out of Amgen (AMGN) in Q2 2021, closing a stake of 1,800 shares — an estimated $448K sold.

Jay D. Rosenbaum first reported a position in AMGN in Q4 2014 and held it in 26 quarters. The position peaked at $2M in Q2 2017. 2,195 funds tracked by Wall St. Rank hold AMGN as of Q2 2021.

  • Jay D. Rosenbaum reported no remaining Amgen position as of Q2 2021 after selling out during the quarter.
  • Jay D. Rosenbaum sold 1,800 Amgen shares in Q2 2021, an estimated $448K.
  • Jay D. Rosenbaum first reported a position in Amgen in Q4 2014 and held it in 26 quarters.
  • Jay D. Rosenbaum's Amgen position peaked at $2M in Q2 2017.
  • 2,195 funds tracked by Wall St. Rank held Amgen as of Q2 2021.

Based on Jay D. Rosenbaum's 13F filing for Q2 2021, filed 14 Jul 2021.